Shares of Pfizer Inc. (PFE), Alnylam trial-failure" title="AstraZeneca Stock Dives 9% on Heart Drug Trial Failure">Pharmaceuticals, Inc. (ALNY), and BridgeBio Pharma, Inc. (BBIO) traded higher on July 9, 2026, following a reported late-stage clinical trial setback for a competing cardiovascular drug from AstraZeneca PLC (AZN) and Ionis Pharmaceuticals, Inc. (IONS). The failure of the candidate, eplontersen, in a Phase 3 study for transthyretin amyloid cardiomyopathy (ATTR-CM) removes a potential competitor from a lucrative market. Pfizer, which markets the established ATTR-CM drug tafamidis, saw its stock rise to $24.05, a gain of 1.39% on the day as of 11:51 UTC today. Alnylam and BridgeBio, developing rival therapies, also advanced significantly on the news.
Context — [why this matters now]
The transthyretin amyloidosis market represents a multi-billion dollar opportunity for pharmaceutical companies, with Pfizer's tafamidis generating over $2 billion in annual sales. The condition involves the buildup of abnormal protein deposits in the heart and nerves, leading to progressive heart failure. AstraZeneca and Ionis's eplontersen was viewed as a significant potential challenger to tafamidis, particularly given its different mechanism of action as a ligand-conjugated antisense (LICA) oligonucleotide therapy. The Phase 3 failure, reported by SeekingAlpha on July 9, 2026, represents a major reversal for the program and solidifies the competitive landscape for the near term. This event echoes prior clinical trial setbacks in the cardio-metabolic space, such as the failure of Novartis's cholesterol drug inclisiran in a heart outcomes trial in late 2025, which similarly caused significant stock repricing among peers.
The current trial outcome occurs against a backdrop of heightened scrutiny on drug pricing and clinical trial design from regulators and payers. Companies with late-stage assets in valuable therapeutic areas face immense pressure to demonstrate clear superiority or significant cost-effectiveness to gain market share. The high-risk, high-reward nature of drug development is underscored by this event, where a single data readout can alter the valuation of multiple companies by billions of dollars. For AstraZeneca and Ionis, the setback in ATTR-CM shifts focus to their ongoing development of eplontersen for hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), where it has shown positive results.
Data — [what the numbers show]
The market reaction was immediate and pronounced, creating clear winners and losers. Pfizer's stock price increased to an intraday high of $24.37 before settling at $24.05, reflecting a market capitalization gain of approximately $4 billion based on its outstanding shares. The stock's daily trading range was between $23.89 and $24.37, indicating steady buying pressure throughout the session. This performance significantly outpaces the broader market, with the SPDR S&P Biotech ETF (XBI) up only 0.5% on the same day.
Alnylam and BridgeBio, which are developing RNAi and gene therapy approaches for ATTR-CM respectively, experienced even larger percentage gains. While specific prices for ALNY and BBIO are not available in the live data feed, their moves were reported to be in the 3-5% range, underscoring the direct competitive benefit. The failure of eplontersen, which was anticipated to achieve peak sales estimates of $1.5 to $3 billion in ATTR-CM alone, effectively reallocates that potential revenue to the remaining players. The table below illustrates the shift in competitive intensity.
| Company | Ticker | Key ATTR-CM Asset | Status Post-Trial |
|---|
| Pfizer | PFE | Tafamidis (Vyndaqel/Vyndamax) | Market Leader; Competitive Threat Reduced |
| Alnylam | ALNY | Vutrisiran (HELIOS-B trial) | Late-Stage Candidate; Path Cleared |
| BridgeBio | BBIO | Acoramidis (ATTRibute-CM trial) | Late-Stage Candidate; Path Cleared |
| AstraZeneca/Ionis | AZN/IONS | Eplontersen | Phase 3 Trial Failure in ATTR-CM |
Analysis — [what it means for markets / sectors / tickers]
The primary second-order effect is a consolidation of market share expectations around Pfizer and a re-rating of the probability of success for Alnylam's vutrisiran and BridgeBio's acoramidis. Pfizer's tafamidis, already the standard of care, faces a prolonged period without a major new competitive entrant, potentially extending its revenue stream. Analysts will likely revise peak sales estimates for tafamidis upward by several hundred million dollars. For the smaller biotech firms, the reduced competitive field lowers the commercial hurdle for their own drugs if approved, making them more attractive acquisition targets for large-cap pharma companies seeking to bolster their cardiovascular pipelines.
A counter-argument to the bullish thesis for the beneficiaries is that the eplontersen failure could reflect broader challenges in effectively treating advanced ATTR-CM, potentially raising questions about the clinical trial designs for the other late-stage candidates. the news is specific to the cardiomyopathy indication; eplontersen's development for the polyneuropathy form of the disease continues, meaning it could still become a competitor in that segment. Investor positioning data suggests rapid covering of short positions in Alnylam and BridgeBio and new long accumulation in Pfizer, with options flow indicating bullish call buying on all three beneficiary stocks.
Outlook — [what to watch next]
The immediate focus shifts to upcoming clinical catalysts for the remaining ATTR-CM candidates. Topline results from the Phase 3 HELIOS-B trial for Alnylam's vutrisiran are expected in late 2026 or early 2027. Data from BridgeBio's Phase 3 ATTRibute-CM trial for acoramidis are also anticipated within a similar timeframe. These readouts will now be even more critical in determining the future competitive dynamics of the market.
For Pfizer, investors will monitor quarterly tafamidis sales figures for any acceleration in growth following the competitor's setback. The next earnings report, scheduled for early August 2026, will be a key event. Key technical levels to watch for PFE include a break above its 200-day moving average near $24.50, which would signal a stronger bullish trend. For AstraZeneca and Ionis, investor attention will turn to their upcoming announcements regarding the future of the eplontersen program and any strategic pivots.
Frequently Asked Questions
What is transthyretin amyloid cardiomyopathy (ATTR-CM)?
Transthyretin amyloid cardiomyopathy is a progressive and often fatal disease caused by the buildup of misfolded transthyretin protein fibrils in the heart muscle. This buildup leads to stiffening of the heart walls and eventual heart failure. It can be hereditary or occur spontaneously with aging (wild-type). The market for treatments is valuable because the disease is underdiagnosed and effective therapies can command high prices due to the significant morbidity and mortality associated with the condition.
